Luc Van Nuffel - Concepedia

Author

Luc Van Nuffel

Janssen (Belgium)

Also Known As

L. van Nuffel, Luc Van Nuffel, Luc van Nuffel

Publications

333

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Janssen (United States)

About

Luc Van Nuffel is an author at Janssen (Belgium) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	151
2	Health Sciences	2	2	86
3	Natural Sciences	2	2	51
4	Biochemistry	2	2	51
5	Engineering	1	1	22

Luc Van Nuffel

Publications

313

Citations

H-Index

Page 1

	Year	Citations
Prevalence of <i>Candida dubliniensis</i> Isolates in a Yeast Stock Collection Frank C. Odds, Luc Van Nuffel, Géry Dams Journal of Clinical Microbiology MycologyBiologyFungal DiversityOral IsolatesC. Dubliniensis Isolates	1998	140
Survival in experimental Candida albicans infections depends on inoculum growth conditions as well as animal host Frank C. Odds, Luc Van Nuffel, Neil A. R. Gow Microbiology Microbial PathogensFungal Cell BiologyClinical MycologyInoculum Growth ConditionsAnaerobic Culturing	2000	74
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy Tianbao Lu, Carsten J. Schubert, Maxwell D. Cummings, Bioorganic & Medicinal Chemistry Letters Cancer TherapyMedicinal ChemistryLipid SynthesisBiochemistryNatural Sciences	2018	37
Opportunities for Hydrogen Energy Technologies Considering the National Energy & Climate Plans Fuel Cell, Hydrogen Joint Undertaking, Frank Gérard, Hydrogen Energy TechnologySteam MethaneHydrogen ProductionEngineeringSustainable Energy	2020	22
Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease Tianbao Lu, Peter J. Connolly, Ulrike Philippar, Bioorganic & Medicinal Chemistry Letters Small-molecule Allosteric InhibitorsBiochemistryNatural SciencesMedicineRational Drug Design	2019	14
Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas Ulrike Philippar, Tianbao Lu, Nele Vloemans, Cancer Research ImmunologyImmune RegulationPathologyImmunoeditingDlbcl Xenografts	2020	14
JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies Janine Arts, Martin Pagé, Annemie Valckx, Chemoprevention StrategyNovel Hdm2 AntagonistPharmacotherapyCancer BiologyHdm2 Gene Amplification	2008	12

Page 1